Immune targeting in breast cancer

ONCOLOGY (United States)

Volumn 29, Issue 5, 2015, Pages

  Cimino Mathews, Ashley ^a   Foote, Jeremy B ^a   Emens, Leisha A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CD137 ANTIGEN; CD20 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; IPILIMUMAB; KI 67 ANTIGEN; LETROZOLE; MESSENGER RNA; MUCIN 1; NIVOLUMAB; PEMBROLIZUMAB; PLASMID DNA; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNINDEXED DRUG;

BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 84929378787     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8.
2. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12:1597-1611.
3. Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 2007;67:1887-92.
4. Denardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: cross-talk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
5. Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011;3(pii):a003285.
6. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;127ra37.
7. Fridman WH, Pages F, Sautes-Fridman, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature Rev Cancer. 2012;12:298-306.
8. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow up. Cancer. 1977;40:1365-85.
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74.
11. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-23.
12. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
13. O’Brien KM, Cole SR, Tse CK, et al. Intrinsic breast cancer subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010;16:6100-10.
14. Schalper KA, Velcheti V, Carvajal D, et al. In situ PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773-82.
15. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;15:5158-65.
16. Rody A, Holtrich U, Pusztai L, et al. T cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11:R15.
17. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13:R97.
18. Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28:316-23.
19. Iglesia MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtypes-specific breast and ovarian cancers. Clin Cancer Res. 2014;20:3818-29.
20. Kristensen VN, Vaske CJ, Ursini-Siegel J, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA. 2012;109:2801-7.
21. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs Working Group 2014. Ann Oncol. 2015;26:259-71.
22. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860-7.
23. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-67.
24. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. Ann Oncol. 2014;25:1544-50.
25. Krieke B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
26. Dieci MV, Cristicello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-8.
27. Mahmoud SM, Paish EC, Powe DG, et al. Tumor infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949-55.
28. Gu-Trantien C, Loi S, Garaud S, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123:273-92.
29. Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132:545-53.
30. Ghebeh H, Barhoush E, Tulbah A, et al. FoxP3+ Tregs and B7-H1/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008;8:57.
31. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373-80.
32. Cimino-Mathews A, Hicks JL, Sharma R, et al. Metastatic breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Human Immunol. 2013;44:2494-500.
33. Mahmoud SM, Lee AH, Paish EC, et al. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65:159-63.
34. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer, and autoimmune disease. Nature Rev Immunol, 2014;14:447-62.
35. Gajewski TJ, Schreiber H, Fu YX. Innate and adaptive cells in the tumor microenvironment. Nature Immunol. 2013;14:1014-22.
36. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6:205-17.
37. Martinet L, Garrido I, Filleron T, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71:5678-87.
38. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105-13.
39. Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793-805.
40. Mao Y, Qu Q, Zhang Y, et al. The value of tumor-infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e115103.
41. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983-91.
42. West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.
43. Generali D, Bates G, Berruti A, et al. Immunomodulation of FoxP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15:1046-51.
44. Demaria S, Volm MD, Shapiro RL, et al. Development of tumor infiltrating lymphocytes in breast cancer after neoadjuvant therapy. Clin Cancer Res. 2001;7:3025-30.
45. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating FoxP3+ regulatory T cells. Clin Cancer Res. 2008;14:2413-20.
46. Ladoire S, Mignot G, Dabakuyo S, et al. In situ immune response after neoadjuvant chemotherapy predicts survival. J Pathol. 2011;224:389-400.
47. Ladoire S, Arnould L, Mignot G, et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer. 2011;105:366-71.
48. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer. 2012;12:252-64.
49. Agata Y, Kwasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765-72.
50. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 1999;5:365-9.
51. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-70.
52. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965-70.
53. Muenst S, Soysal SD, Gao F, et al. The presence of programmed death-1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139:667-76.
54. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190-8.
55. Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326-32.
56. Schalper KA, Velcheti V, Carvajal D, et al. In situ PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773-82.
57. Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in breast cancer. Breast Cancer Res Treat. 2014;146:15-24.
58. Brignone C, Gutierrez M, Mefti F, et al. First line chemoimmunotherapy in metastatic breast carcinoma: combinations of paclitaxel and IMG-321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8:71.
59. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in metastatic melanoma. N Engl J Med. 2010;363:711-23.
60. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
61. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunother. 2013;5:215-29.
62. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16:3485-94.
63. Lipson EJ, Forde PM, Hammers H-J, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015; in press.
64. Robert C, Long GV, Brady B, et al. Nivolumab in previously treated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30.
65. Nanda R, Chow L, Dees E, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Presented at 2014 San Antonio Breast Cancer Symposium; Dec 9-13, 2014; San Antonio, TX. Abstr S1-09.
66. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
67. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;55:558-62.
68. Emens L, Braiteh F, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple negative breast cancer. Presented at 2014 San Antonio Breast Cancer Symposium; 2014 Dec 9-13; San Antonio, TX. Poster PD1-6.
69. Emens L, Braiteh F, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple negative breast cancer. Presented at 2015 Annual Meeting of the American Association of Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Abstr 6317.
70. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5:1289-97
71. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002;8:1014-18.
72. Disis ML, Schiffman K, Gooley TA, et al. Delayed type hypersensitivity is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6:1347-50.
73. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J Clin Invest. 2001;107:477-84.
74. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20:2624-32.
75. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide-based vaccine in cancer patients. J Clin Immunol. 2004;24:571-8.
76. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J Clin Oncol. 2004;22:1916-25.
77. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER-2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685-92.
78. Hamilton E, Blackwell K, Hobeika AC, et al. Phase I clinical trial of HER-2-specific immunotherapy with concomitant HER-2 kinase inhibition. J Transl Med. 2012;10:28.
79. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte-macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8:3407-18.
80. Miles D, Roché H, Martin M, et al. Theratope Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011:16:1092-1100.
81. Tiriveedhi V, Tucker N, Herndon J, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res. 2014;20:5964-75.
82. Park JW, Melisko ME, Esserman LJ, et al. Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunology and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol. 2007;25:3680-7.
83. Svane IM, Pedersen AE, Johansen JS, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer: monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 2007;56:1485-99.
84. Davis-Sproul JM, Harris MP, Davidson NE, et al. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy. 2005;7:46-56.
85. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med. 2010;10:52-60.
86. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27:5911-8.
87. Chen G, Leatherman JM, Sunay ME, Emens LA. Cyclophosphamide selectively induces dose-dependent apoptosis of CD4+FoxP3+ regulatory T cells relative to CD4+FoxP3- effector T cells in breast cancer patients. Cancer Res. 2013;73(8 suppl):abstr 4749. Available from: http://cancerres.aacrjournals.org/content/73/8_Supplement/4749.short. Accessed April 14, 2015.
88. Chen G, Gupta R, Petrik S, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting tumor vaccine for HER-2+ metastatic breast cancer. Cancer Immunol Res. 2014;2:949-61.
89. Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735-42.
90. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER-2/neu expression level on response to the E75 vaccine: from the US Military Institute Clinical Trials Study Group Study I-01 and I-02. Clin Cancer Res. 2009;15:2895-2904.
91. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842-52.
92. Sharma A, Koldovsky U, Xu S, et al. HER-2-pulsed dendritic cells can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012;118:4354-62.